Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center

Knight, Jason S.; Tsodikov, Alexander; Cibrik, Diane M.; Ross, Charles W.; Kaminski, Mark; Blayney, Douglas W.

doi:10.1200/jco.2008.20.0857

Cited by 177 publications

(170 citation statements)

References 45 publications

Supporting

Mentioning

156

Contrasting

Order By: Relevance

“…(Faull et al, 2005;Webber et al, 2006).More recent data suggest that the median time is later, at approximately 3 years after SOT. ( Evens et al, 2010;Ghobrial et al, 2010;Knight et al, 2009;Maecker et al, 2007) This is partly due to an increase in the diagnosis of EBV-unrelated disease. Multiple reports have shown that EBV-unrelated PTLD occurs later after SOT, most commonly after 3 to 5 years.…”

Section: Ebv+ Vs Ebv-mentioning

confidence: 99%

“…(Dotti et al, 2002;Leblond et al, 1998;Nelson et al, 2000;Taylor et al, 2005) Recent data shows an improved response to treatment, which could be explained both by improvements in treatment strategies of the tumors and by improved supportive care. (Elstrom et al, 2006;Evens et al, 2010;Knight et al, 2009;Maecker et al, 2007) …”

Section: Ebv+ Vs Ebv-mentioning

confidence: 99%

“…(Buell et al, 2005;Knight et al, 2009;Maecker et al, 2007) It is more commonly associated with EBV. (Choquet et al, 2008) The optimal therapy for CNS PTLD is not known and proposed treatment approaches include high-dose methotrexate-based therapy, intrathecal chemotherapy and intrathecal rituxumab.…”

Section: Isolated Cns Ptldmentioning

confidence: 99%

See 2 more Smart Citations

Posttransplant Lymphoproliferative Disorders Following Solid Organ Transplantation

Rodríguez¹,

Punnett²

2012

Organ Donation and Transplantation - Public Policy and Clinical Perspectives

View full text Add to dashboard Cite

Section: Ebv+ Vs Ebv-mentioning

confidence: 99%

Section: Ebv+ Vs Ebv-mentioning

confidence: 99%

See 1 more Smart Citation

Posttransplant Lymphoproliferative Disorders Following Solid Organ Transplantation

Rodríguez¹,

Punnett²

2012

Organ Donation and Transplantation - Public Policy and Clinical Perspectives

View full text Add to dashboard Cite

“…Since PTLD arise in only 1.0 ± 0.3% of all transplant recipients, [22][23][24] it is likely that other conditions have to be present to allow the emergence of the disease (e.g. a particular cytokine milieu, as reviewed by Burns and Crawford 25 ).…”

Section: Ebv-related Malignancies In Immunocompromised Hostsmentioning

confidence: 99%

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

Merlo¹,

Turrini²,

Dolcetti³

et al. 2010

Haematologica

View full text Add to dashboard Cite

The Epstein-Barr virus has evolved a plethora of strategies to evade immune system recognition and to establish latent infection in memory B cells, where the virus resides lifelong without any consequence in the majority of individuals. However, some imbalances in the equilibrium between the inherent virus transforming properties and the host immune system can lead to the development of different tumors, such as lymphoproliferative disorders, Hodgkin's lymphoma, Burkitt's lymphoma, and nasopharyngeal carcinoma. The expression of viral antigens in malignant cells makes them suitable targets for immunotherapeutic approaches, which are mainly based on the ex vivo expansion of EBV-specific T cells. Indeed, the infusion of virus-specific cytotoxic T lymphocytes has proved not only to be safe and effective, but also capable of restoring or inducing a protective anti-virus immunity, which is lacking, albeit to a different extent, in every EBV-driven malignancy. The purpose of this review is to summarize the results of adoptive immunotherapy approaches for EBV-related malignancies, with particular emphasis on the immunological and virological aspects linked to the clinical responses obtained. Data collected confirm the clinical relevance of the use of EBV-specific cytotoxic T lymphocytes in the field of adoptive immunotherapy and suggest the increasing importance of this approach also against other tumors, concurrent with the increasing knowledge of the intimate and continuous interplay between the virus and the host immune system. -related disorders. Haematologica 210;95(10):1769-1777. doi:10.3324/haematol.2010 Citation: Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, and Rosato A. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV ©2010 Ferrata Storti Foundation. This is an open-access paper.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

show abstract

“…Posttransplant lymphoproliferative disorders (PTLDs), a group of B-cell (and less frequently, T-cell) lymphomas, develop as a complication of immunosuppression in patients undergoing organ transplant [1]. The first report of PTLD was in 1969 [2] by Penn and colleagues, but since then, it has been reported after different kinds of organ transplant and has become an entity of interest and research worldwide.…”

mentioning

confidence: 99%

Posttransplant lymphoproliferative disorder after living donor liver transplant: are we improving incidence and outcome?

Tadmor

Polliack²,

Sweetenham

2010

Leukemia & Lymphoma

View full text Add to dashboard Cite

Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center

Cited by 177 publications

References 45 publications

Posttransplant Lymphoproliferative Disorders Following Solid Organ Transplantation

Posttransplant Lymphoproliferative Disorders Following Solid Organ Transplantation

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

Posttransplant lymphoproliferative disorder after living donor liver transplant: are we improving incidence and outcome?

Contact Info

Product

Resources

About